LivaNova (NASDAQ:LIVN) Updates FY 2025 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 3.800-3.90 for the period, compared to the consensus estimate of 3.550. The company issued revenue guidance of -, compared to the consensus revenue estimate of $1.4 billion.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of LivaNova in a research note on Wednesday, October 8th. Robert W. Baird upped their price target on LivaNova from $61.00 to $63.00 and gave the company an “outperform” rating in a report on Thursday. The Goldman Sachs Group set a $55.00 price objective on LivaNova and gave the stock a “neutral” rating in a report on Wednesday, October 1st. Needham & Company LLC reissued a “buy” rating and issued a $64.00 target price on shares of LivaNova in a research report on Wednesday, September 3rd. Finally, Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, LivaNova presently has an average rating of “Moderate Buy” and a consensus target price of $60.00.

LivaNova Stock Performance

Shares of LivaNova stock traded up $0.86 during trading hours on Friday, reaching $50.43. 459,471 shares of the stock traded hands, compared to its average volume of 665,940. LivaNova has a one year low of $32.48 and a one year high of $58.91. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of -12.96 and a beta of 1.00. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The company has a 50 day moving average price of $54.13 and a 200 day moving average price of $48.14.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.91 by $0.20. The company had revenue of $357.80 million for the quarter, compared to the consensus estimate of $342.32 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm’s revenue was up 12.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.90 earnings per share. LivaNova has set its FY 2025 guidance at 3.800-3.90 EPS. On average, equities research analysts expect that LivaNova will post 2.85 earnings per share for the current fiscal year.

Hedge Funds Weigh In On LivaNova

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. increased its position in LivaNova by 714.7% in the second quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock worth $46,313,000 after buying an additional 902,447 shares in the last quarter. Scopia Capital Management LP bought a new position in shares of LivaNova during the 2nd quarter valued at approximately $36,657,000. AQR Capital Management LLC increased its holdings in LivaNova by 30.5% in the 2nd quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock worth $92,201,000 after acquiring an additional 478,525 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in LivaNova by 645.3% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 135,824 shares of the company’s stock worth $6,115,000 after acquiring an additional 117,601 shares in the last quarter. Finally, Armistice Capital LLC bought a new stake in LivaNova during the 2nd quarter worth approximately $2,746,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.